IX BIOPHARMA EUROPE LIMITED

IX Biopharma Europe Limited is a biopharmaceutical innovator focused on redefining drug delivery through its proprietary WaferiX platform – a novel sublingual wafer technology that offers superior bioavailability, rapid onset and predictable therapeutic effect. By harnessing a patented, GMP‑certified manufacturing process, the company repurposes existing small‑molecule actives and delivers them via fast‑dissolving wafers, improving absorption, patient compliance and extending product life‑cycles.

The firm’s pipeline spans several therapeutic areas. Its lead candidate, Wafermine, is a sublingual racemic ketamine wafer currently poised for Phase 3 trials, showing strong analgesic and opioid‑sparing benefits for acute moderate‑to‑severe pain. Complementary products include BnoX (sublingual buprenorphine for pain), Wafesil (sublingual sildenafil for erectile dysfunction), award‑winning sublingual medicinal‑cannabis wafers and next‑generation nutraceuticals under the Entity brand. IX Biopharma’s focus on repurposed actives with established safety profiles enables faster, cost‑effective development pathways, delivering innovative therapies that enhance quality of life for patients with pain, chronic conditions and other debilitating diseases.